CMS Removes the Main Medicare Brake on Symptomatic TAVR

Medicare has opened the door wider for symptomatic TAVR, shifting competition toward approved platforms and high-capacity structural heart programs.

Updated

What is this trend?

CMS has lifted the main Medicare coverage barrier for symptomatic TAVR, making access easier for approved valve systems while keeping strict procedural and volume requirements in place.

  • Symptomatic severe aortic stenosis now has broader Medicare access under FDA-approved complete TAVR systems.
  • CMS kept asymptomatic severe AS under CED, so the biggest coverage change is still targeted.
  • Hospitals and heart teams must meet volume, review, and procedural standards to capture demand.
  • The market shifts from reimbursement access to execution, capacity, and referral capture.
  • Value accrues to PMA-backed TAVR platforms and the imaging and delivery tools around them.

What’s the latest?

CMS this week removed Coverage with Evidence Development for TAVR in symptomatic severe aortic stenosis when performed under an FDA-approved indication using a complete valve and implantation system w

Regulatory Proof Tightens for AI Diagnostics, Workflow-Embedded Monetization Expands, and Reimbursement Finds Existing Codes

How it developed

  1. Compliance, reimbursement, and localization are reshaping medtech competition
    • Outpatient Workflow and Infection Control Are Reallocating Device Demand

  2. Regulated AI Workflow Expansion, Platform Consolidation, and CMS Easing on TAVR
    • CMS Removes the Main Medicare Brake on Symptomatic TAVR

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Medical Devices & Tools

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.